According to sources familiar with the matter, healthcare giant Johnson & Johnson is conducting a strategic review of its orthopedics division, which may involve adjustments to the future direction of the department.

Affected by this news, Johnson & Johnson's stock price saw a brief surge during the session, ultimately closing with a 0.5% gain. Market analysts pointed out that the orthopedics business, as an important part of Johnson & Johnson's medical device segment, will directly impact the company's overall business layout through its strategic adjustments. This assessment may include business restructuring, adjustments to partnerships, or potential strategic options. Investors are closely watching the possible structural changes brought about by this evaluation, believing it could be a key move for Johnson & Johnson to optimize its product portfolio and enhance its market competitiveness. The immediate reaction in the stock price also reflects the market's positive expectations for potential business adjustments.